Testosterone Enanthate Injection — CPB 1015 | AETNA Coverage Update

Aetna modified CPB 1015 for testosterone enanthate injection, effective September 26, 2025. Here's what billing teams need to know before your next claim goes out.

Aetna, a CVS Health company, updated its testosterone enanthate injection coverage policy under CPB 1015 Aetna system. The primary billing code at stake is HCPCS J3121 (injection, testosterone enanthate, 1 mg), with supporting CPT codes 84402, 84403, 84410, 96372, and 99506 also in scope. This policy governs medical necessity for a drug used across several distinct clinical indications — and the criteria differ enough between them that a single billing misstep can generate a claim denial.

Quick-Reference Table

Aetna Testosterone Enanthate Coverage Criteria and Medical Necessity Requirements 2025

The Aetna testosterone enanthate coverage policy under CPB 1015 covers J3121 under five distinct indications. Each has its own medical necessity checklist. Miss one item, and you're looking at a denial.

Indication 1: Primary or hypogonadotropic hypogonadism (ICD-10 E29.1 or E23.0). Aetna requires at least two confirmed low morning testosterone levels before therapy starts. Both values must fall below the reference laboratory range or current practice guidelines. One low result isn't enough. Make sure labs for CPT 84402 (testosterone, free), 84403 (total), or 84410 (bioavailable) are in the chart and dated before the first injection.

Indication 2: Gender dysphoria (ICD-10 F64.0–F64.9). For adult members, all five criteria must be met: confirmed gender dysphoria diagnosis, documented ability to make an informed decision, reasonably controlled comorbid conditions, education on contraindications and side effects, and documentation that fertility preservation options were discussed. Every single one. Not four out of five.

For adolescent members with gender dysphoria, the bar is higher. Six criteria must be met — everything in the adult list plus documented Tanner stage 2 puberty or greater. The prescribing provider must be a specialist in transgender youth care (pediatric endocrinologist, family/internal medicine physician, or OB/GYN) and must collaborate with a mental health provider for members under 18. That collaboration needs to be in the record, not just implied.

Indication 3: Inoperable metastatic breast cancer (ICD-10 C50.011–C50.929). Two criteria apply: the member must be one to five years postmenopausal, and there must be documented incomplete response to prior therapy for metastatic breast cancer. Both conditions are required.

Indication 4: Hormone-responsive breast cancer in premenopausal members (ICD-10 C50.011–C50.929). Aetna covers J3121 here when the member has benefited from oophorectomy and has a documented hormone-responsive tumor. "Benefited from" means documented clinical response — not just that oophorectomy was performed.

Indication 5: Delayed puberty (ICD-10 E30.0). The policy lists this as a covered indication without additional criteria stated in this section. Still document it thoroughly — Aetna will want diagnosis support on any prior authorization review.

Continuation of therapy also has its own criteria. Coverage continues when the member is tolerating therapy and shows clinical benefit — for hypogonadism that means a response in relevant lab values or clinical symptoms, for gender dysphoria it means ongoing diagnosis and treatment appropriateness. Don't assume an approved initial claim means continuation is automatic.

Aetna Testosterone Enanthate Exclusions and Non-Covered Indications

Aetna considers all indications outside the five listed above experimental, investigational, or unproven. Full stop.

The big one your team needs to flag: performance enhancement is not covered under any Aetna plan. Most plans have an explicit benefit exclusion for steroids used for performance enhancement. For plans that don't carry that specific exclusion, Aetna still denies coverage on the grounds that performance enhancement in non-diseased individuals doesn't qualify as treatment of disease or injury.

Two ICD-10 codes in the policy data are worth watching: F52.0 (hypoactive sexual desire disorder) and F52.22 (female sexual arousal disorder). These codes are listed in the policy — but they're in the "other CPT codes related to the CPB" group, not tied to covered indications. If you're billing J3121 for these diagnoses, expect scrutiny. Talk to your compliance officer before billing these as primary diagnoses.

Similarly, R41.81 (age-related cognitive decline) appears in the code data. This maps to "improvement of cognitive function in aging men" — a use case Aetna considers investigational. Don't use this as a supporting diagnosis on J3121 claims.

Heart failure codes I50.1–I50.9 also appear in the dataset. These likely relate to monitoring requirements or comorbidity documentation, not as covered indications. They're not standalone justification for testosterone enanthate reimbursement.

Coverage Indications at a Glance

Aetna Testosterone Enanthate Billing Guidelines and Action Items 2025

The effective date is September 26, 2025. Claims submitted after that date fall under the updated CPB 1015 criteria. Here's what your billing team needs to do now.

CPT, HCPCS, and ICD-10 Codes for Testosterone Enanthate Under CPB 1015

Covered HCPCS Code (When Selection Criteria Are Met)

Supporting CPT Codes

Key ICD-10-CM Diagnosis Codes